🎉 M&A multiples are live!
Check it out!

Oxford BioMedica Valuation Multiples

Discover revenue and EBITDA valuation multiples for Oxford BioMedica and similar public comparables like Suven Pharma, Syngene International, and Jubilant Pharmova.

Oxford BioMedica Overview

About Oxford BioMedica

Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types.


Founded

1996

HQ

United Kingdom of Great Britain and Northern Ireland
Employees

714

Website

oxb.com

Financials

LTM Revenue $178M

LTM EBITDA -$13.4M

EV

$443M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Oxford BioMedica Financials

Oxford BioMedica has a last 12-month revenue of $178M and a last 12-month EBITDA of -$13.4M.

In the most recent fiscal year, Oxford BioMedica achieved revenue of $115M and an EBITDA of -$191M.

Oxford BioMedica expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Oxford BioMedica valuation multiples based on analyst estimates

Oxford BioMedica P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $180M $115M XXX XXX XXX
Gross Profit $106M $89.1M XXX XXX XXX
Gross Margin 59% 77% XXX XXX XXX
EBITDA -$14.0M -$191M XXX XXX XXX
EBITDA Margin -8% -166% XXX XXX XXX
Net Profit $24.5M -$50.4M XXX XXX XXX
Net Margin 14% -44% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Oxford BioMedica Stock Performance

As of April 15, 2025, Oxford BioMedica's stock price is GBP 3 (or $4).

Oxford BioMedica has current market cap of GBP 296M (or $381M), and EV of GBP 344M (or $443M).

See Oxford BioMedica trading valuation data

Oxford BioMedica Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$443M $381M XXX XXX XXX XXX $-0.47

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Oxford BioMedica Valuation Multiples

As of April 15, 2025, Oxford BioMedica has market cap of $381M and EV of $443M.

Oxford BioMedica's trades at 2.5x LTM EV/Revenue multiple, and -32.9x LTM EBITDA.

Analysts estimate Oxford BioMedica's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Oxford BioMedica and 10K+ public comps

Oxford BioMedica Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $443M XXX XXX XXX
EV/Revenue 3.8x XXX XXX XXX
EV/EBITDA -2.3x XXX XXX XXX
P/E -1.9x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -9.0x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Oxford BioMedica Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Oxford BioMedica Valuation Multiples

Oxford BioMedica's NTM/LTM revenue growth is 26%

Oxford BioMedica's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.2M for the same period.

Over next 12 months, Oxford BioMedica's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Oxford BioMedica's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Oxford BioMedica and other 10K+ public comps

Oxford BioMedica Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -36% XXX XXX XXX XXX
EBITDA Margin -166% XXX XXX XXX XXX
EBITDA Growth 1268% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -140% XXX XXX XXX XXX
Revenue per Employee $0.2M XXX XXX XXX XXX
Opex per Employee $0.2M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 28% XXX XXX XXX XXX
R&D Expenses to Revenue 66% XXX XXX XXX XXX
Opex to Revenue 140% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Oxford BioMedica Public Comps

See public comps and valuation multiples for Contract Research & Manufacturing and Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Jubilant Pharmova XXX XXX XXX XXX XXX XXX
Biocon XXX XXX XXX XXX XXX XXX
Syngene International XXX XXX XXX XXX XXX XXX
Dishman Carbogen Amics XXX XXX XXX XXX XXX XXX
Suven Pharma XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Oxford BioMedica M&A and Investment Activity

Oxford BioMedica acquired  XXX companies to date.

Last acquisition by Oxford BioMedica was  XXXXXXXX, XXXXX XXXXX XXXXXX . Oxford BioMedica acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Oxford BioMedica

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Oxford BioMedica

When was Oxford BioMedica founded? Oxford BioMedica was founded in 1996.
Where is Oxford BioMedica headquartered? Oxford BioMedica is headquartered in United Kingdom of Great Britain and Northern Ireland.
How many employees does Oxford BioMedica have? As of today, Oxford BioMedica has 714 employees.
Who is the CEO of Oxford BioMedica? Oxford BioMedica's CEO is Dr. Frank Mathias.
Is Oxford BioMedica publicy listed? Yes, Oxford BioMedica is a public company listed on LON.
What is the stock symbol of Oxford BioMedica? Oxford BioMedica trades under OXB ticker.
When did Oxford BioMedica go public? Oxford BioMedica went public in 2001.
Who are competitors of Oxford BioMedica? Similar companies to Oxford BioMedica include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics.
What is the current market cap of Oxford BioMedica? Oxford BioMedica's current market cap is $381M
What is the current revenue of Oxford BioMedica? Oxford BioMedica's last 12-month revenue is $178M.
What is the current EBITDA of Oxford BioMedica? Oxford BioMedica's last 12-month EBITDA is -$13.4M.
What is the current EV/Revenue multiple of Oxford BioMedica? Current revenue multiple of Oxford BioMedica is 2.5x.
What is the current EV/EBITDA multiple of Oxford BioMedica? Current EBITDA multiple of Oxford BioMedica is -32.9x.
What is the current revenue growth of Oxford BioMedica? Oxford BioMedica revenue growth between 2023 and 2024 was -36%.
Is Oxford BioMedica profitable? Yes, Oxford BioMedica is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.